Advanced Kidney Cancer Pipeline Outlook 2025

Strategic Insights -

The Advanced Kidney Cancer pipeline landscape is marked by 50+ companies and 55+ pipeline drugs, with a majority of these therapies in various stages of clinical trials. AstraZeneca's Savolitinib and Bristol-Myers Squibb's Relatlimab are among the notable pipeline drugs for Advanced Kidney Cancer treatment. The pipeline report highlights the key companies, pipeline therapies, and unmet needs in the space.

Key Takeaways:

  • M.D. Anderson Cancer Center announced a Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma, with primary objectives to determine the efficacy of objective response rate (ORR) and 24-week disease control rate (DCR).
  • Hoffmann-La Roche conducted a study to evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
  • DelveInsight's pipeline report offers insights into 50+ companies and 55+ pipeline drugs, with a comprehensive overview of the pipeline landscape.
  • The report covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products, and provides a detailed analysis of the pipeline therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The pipeline report provides a robust space with 50+ active players working to develop 55+ pipeline therapies for Advanced Kidney Cancer treatment.
  • Promising pipeline therapies include TQB2450, Sunitinib, Anlotinib, epothilone b, HB0025, Ipilimumab, RAD001, Belzutifan, Famitinib, L19IL2, Bevacizumab, and others.

Statistics:

  • 50+ companies are working on 55+ pipeline therapies for Advanced Kidney Cancer treatment.
  • The pipeline report features a comprehensive overview of the pipeline landscape, including 55+ pipeline drugs and 50+ companies.
  • The pipeline report highlights the key companies and pipeline therapies, as well as the unmet needs in the space.
  • Advanced Kidney Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration (ROA).
  • Advanced Kidney Cancer pipeline report highlights the therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Kidney Cancer treatment.

Sources:

  • M2 PressWIRE-August 26, 2025-: Advanced Kidney Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
  • DelveInsight's, "Advanced Kidney Cancer Pipeline Insight, 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape
  • www.abnewswire.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.m2.co.uk on the world wide web. Inquiries to info@m2.co.uk))
  • DelveInsight's is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions.